Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Sunday, Wall Street Zen reports.

A number of other analysts have also weighed in on the company. HC Wainwright initiated coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 target price for the company. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a report on Wednesday, July 8th. BTIG Research lowered their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. Finally, Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tvardi Therapeutics Price Performance

NASDAQ TVRD opened at $1.14 on Friday. The stock’s 50 day simple moving average is $1.74 and its 200 day simple moving average is $2.63. Tvardi Therapeutics has a one year low of $0.93 and a one year high of $43.65. The firm has a market cap of $15.21 million, a PE ratio of -0.41 and a beta of 0.38.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, equities analysts expect that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP acquired a new stake in Tvardi Therapeutics in the second quarter worth $63,000. BlackRock Inc. acquired a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $181,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Tvardi Therapeutics in the second quarter valued at approximately $34,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.